Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy and safety of ruxolitinib (median follow-up, 2 year...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W.N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Sun, William, Sandor, Victor, Kantarjian, Hagop M.
Format: Artigo
Sprog:Inglês
Udgivet: Ferrata Storti Foundation 2013
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3856961/
https://ncbi.nlm.nih.gov/pubmed/24038026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.092155
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker